Competitor Evaluation in Biosimilar & Biosuperior Therapeutic Antibody Field in New La Merie Publishing Study Available at MarketPublishers.com
24 Mar 2014 • by Natalie Aster
LONDON – At present, marketed antibodies are regarded to be attractive for various companies involved in the elaboration of the next generation variants as well as biosimilar copies, as they represent commercially and clinically validated products. Novel technologies like Fc engineering, antibody drug conjugates/bispesific molecules, polyclonal mixtures and the expiration of patents are driving the introduction (discovery) and development of biosimilar and biosuperior molecules.
By end-2013, the combined value of sales of recombinant therapeutic monoclonal antibodies coming from companies based and operating in regulated markets reached around USD 75.7 billion. Meantime, the cumulated value of sales of branded therapeutic antibodies reaching patent expiry and hence target of biosimilar substitution, stood at USD 58.6 billion.
New research report “Competitor Analysis: Biosimilar and Biosuperior Therapeutic Antibodies 2014” prepared by La Merie Publishing offers a detailed and unbiased competitor evaluation in the sector of recombinant polyclonal and monoclonal antibodies in the biosimilar and biosuperior marketplace.
The research study presents an all-round analysis of the biosimilar and biosuperior therapeutic antibodies field, thoroughly examining the current pipeline. The topical report provides a list of the branded products available in the market and uncovers their sales statistics in 2013, discloses their up-side indications in development, and reviews the biosuperior and biosimilar antibody drug candidates currently being under development. It contains a compilation of presently active projects in R&D of biosimilar and biosuperior antibodies against clinically and commercially validated targets.
Products covered in the report include, among others, Simponi, Rituxan/MabThera, Nulojix, Vectibix, Arzerra, Zevali, Gazyva, Herceptin, Perjeta, Kadcyla, Avastin, Zaltrap, Erbitux, XGEVA, Yervoy, Poteligeo, Humira, Adcetris, Enbrel, Remicade, Cimzia, Orencia, Ilaris, Arcalyst, Tysabri, Soliris, Xolair, Stelara, Actemra/RoActemra, Benlysta, Lemtrada, ReoPro, Nplate, Prolia, Lucentis, Eylea and Synagis.
Competitor Analysis: Biosimilar and Biosuperior Therapeutic Antibodies 2014
Published: March, 2013
Price: US$ 1,523.00
Other Recent Competitor Analysis Reports by La Merie Publishing Include:
- Competitor Analysis: EGF-R Antibodies –Biosimilars and Biosuperiors
- Competitor Analysis: TNF Antibodies –Biosimilars and Biosuperiors
- Competitor Analysis: Her2 Antibodies - Trastuzumab Biosimilars and Biobetters/Biosuperiors
More new market research reports by the publisher can be found at La Merie Publishing page.